Início › Mieloma Múltiplo › Maryland › Baltimore
Ensaios clínicos de Mieloma Múltiplo em Baltimore, MD
13 estudos para Mieloma Múltiplo estão buscando participantes em locais em Baltimore e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 3
- Johns Hopkins Hospital, Baltimore
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 3
- University of Maryland School of Medicine, Baltimore
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecrutandoFase 3
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecrutandoFase 1 inicial
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecrutandoFase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Collection of Tissue Samples for Cancer Research
RecrutandoEstudo observacional
- Johns Hopkins University, Baltimore
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
RecrutandoFase 3
- University of Maryland | Greenebaum Cancer Center, Baltimore
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecrutandoFase 3
- Research Site, Baltimore
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RecrutandoFase 1
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecrutandoFase 3
- Greater Baltimore Medical Center, Baltimore
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecrutandoFase 3
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecrutandoFase 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1/2
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ensaios de Mieloma Múltiplo em outras cidades
- New York City, NY60 estudos
- Boston, MA42 estudos
- Atlanta, GA41 estudos
- Houston, TX38 estudos
- Durham, NC37 estudos
- Nashville, TN32 estudos
- Denver, CO27 estudos
- Rochester, MN24 estudos
- St. Louis, MO24 estudos
- Columbus, OH24 estudos
- Baldwin Park, CA23 estudos
- Chicago, IL22 estudos
Outros estudos em Baltimore
- Câncer de Pulmão de Não Pequenas Células60 estudos
- Câncer de Mama47 estudos
- Câncer de Próstata43 estudos
- Câncer de Pulmão40 estudos
- Câncer (todos os tipos)37 estudos
- Câncer Colorretal31 estudos
- Câncer de Pâncreas31 estudos
- Câncer Metastático28 estudos
- Obesidade25 estudos
- Insuficiência Cardíaca24 estudos
- Câncer de Bexiga24 estudos
- Acidente Vascular Cerebral22 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.